ERBB2 and breast carcinoma: Furthermore, tGLI1 and IL-6/IL-6R/GP130 were significantly co-activated in HER2-enriched breast cancer and TNBC when compared to luminal patients, as validated by two separate breast cancer datasets, The Cancer Genome Atlas (TCGA) (Figure 1E) and the Gene Expression Omnibus (GEO) (Figure 1F).